financetom
MEDP
financetom
/
Healthcare
/
MEDP
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Medpace Holdings, Inc.MEDP
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.

It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.

Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Latest News >
Salesforce forecasts second-quarter revenue below estimates
Salesforce forecasts second-quarter revenue below estimates
May 29, 2024
(Reuters) - Salesforce ( CRM ) forecast second-quarter revenue below Wall Street expectations on Wednesday, on weak client spending on its cloud and enterprise business products in an uncertain economy, sending its shares down 9% in extended trading. The company forecast revenue between $9.20 billion and $9.25 billion compared with estimates of $9.37 billion, according to LSEG data. Salesforce's (...
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Price: 62.20, Change: -0.81, Percent Change: -1.28 ...
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
May 29, 2024
04:09 PM EDT, 05/29/2024 (MT Newswires) -- Price: 27.10, Change: +3.18, Percent Change: +13.29 ...
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Timothy J Scannell, Director, on May 28, 2024, sold 3,300 shares in Insulet ( PODD ) for $596,970. Following the Form 4 filing with the SEC, Scannell has control over a total of 42,586 shares of the company, with 42,586 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1145197/000112760224016771/xslF345X03/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved